1	Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic
2	fibrosis
3	Ryan Marsh <sup>a</sup> , Claudio Dos Santos <sup>b</sup> , Alexander Yule <sup>c,d</sup> , Neele S Dellschaft <sup>e</sup> , Caroline L Hoad <sup>e</sup> ,
4	Christabella Ng <sup>c,d</sup> , Giles Major <sup>c,f</sup> , Alan R Smyth <sup>c,d,g</sup> , Damian Rivett <sup>b*</sup> , Christopher van der Gast <sup>a,h *</sup>
5	
6	<sup>a</sup> Department of Applied Sciences, Northumbria University, Newcastle, UK
7	<sup>b</sup> Department of Natural Sciences, Manchester Metropolitan University, UK
8	° School of Medicine, University of Nottingham, UK
9	<sup>d</sup> NIHR Nottingham Biomedical Research Centre, UK
10	e Sir Peter Mansfield Imaging Centre, University of Nottingham, UK
11	<sup>f</sup> Nestlé Institute of Health Sciences, Société des Produits Nestlé, Lausanne, Switzerland
12	<sup>g</sup> School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK
13	<sup>h</sup> Department of Respiratory Medicine, Northern Care Alliance NHS Foundation Trust, Salford, UK
14	
15	* Correspondence to: Professor Chris van der Gast, Department of Applied Sciences, Ellison Building,
16	Newcastle upon Tyne, NE1 8ST, UK; chris.vandergast@northumbria.ac.uk
17	Dr Damian Rivett, Department of Natural Sciences, John Dalton Building, Chester Street, Manchester,
18	M1 5GD, UK; D.Rivett@mmu.ac.uk
19	

20 Keywords: gut microbiome, dysbiosis, pulmonary antibiotics, CFTR modulator therapy, Kaftrio, Trikafta

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 21 Abstract

Background: There is a paucity of knowledge on the longer-term effects of CF transmembrane
conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes.
In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut
microbiota, metabolomic functioning, and clinical outcomes in people with CF (pwCF).

26

Study design: Faecal samples from 20 pwCF were acquired before and then following 3, 6, and 17+
months of ETI therapy. Samples were subjected to microbiota sequencing and targeted metabolomics
to profile and quantify short-chain fatty acid composition. Ten healthy matched controls were included
for comparison. Clinical data, including markers of intestinal function were integrated to investigate
relationships.

32

33 *Results*: Extended ETI therapy increased core microbiota diversity and composition, which translated 34 to gradual shifts in whole microbiota composition towards that observed in healthy controls. Despite 35 becoming more similar over time, CF microbiota and functional metabolite compositions remained 36 significantly different to healthy controls. Antibiotic treatment for pulmonary infection significantly 37 explained a relatively large degree of variation within the whole microbiota and rarer satellite taxa. 38 Clinical outcomes were not significantly different following ETI.

39

40 *Conclusions*: A positive trajectory towards the microbiota observed in healthy controls was found. 41 However, we posit that progression was predominately impeded by pulmonary antibiotics 42 administration. We recommend future studies use integrated omics approaches within a combination 43 of long-term longitudinal patient studies and model experimental systems. This will deepen our 44 understanding of the impacts of CFTR modulator therapy and respiratory antibiotic interventions upon 45 the gut microbiome and gastrointestinal pathophysiology in CF.

#### 46 **1. Introduction**

47 Alongside the classical respiratory complications of cystic fibrosis (CF) are also the gastrointestinal 48 abnormalities of disease. People with CF (pwCF) suffer from persistent intestinal symptoms and 49 abnormalities that impact both morbidity and mortality [1]. This has continued despite the transition of 50 treatment for CF entering the phase of highly effective CFTR modulator therapies, which correct the 51 underlying defect of chloride and bicarbonate transport across epithelial surfaces of the body [2]. 52 Although the majority of pwCF are now receiving CFTR modulator based therapy [3], the need to better 53 understand the relationships between intestinal symptoms and abnormalities persists, as determined 54 by pwCF, carers, and clinicians [4,5]. It is understood that intestinal dysbiosis, that is the disruption of 55 the microbial communities inhabiting the intestinal tract, is frequent in CF and leads to compositions of 56 bacteria distinctly different from healthy controls from birth and throughout adulthood [6-8]. Whilst this 57 could be further compounded by the CF-associated lifestyle, such as dietary habits and frequent 58 antibiotic usage [9,10], disruption of CFTR activity alone is seemingly sufficient to elicit structural 59 changes to the microbiota [11]. Furthermore, the altered gut microbiota in pwCF has previously been 60 associated with various manifestations of the GI tract [12-14]. Given this evidence, it is possible that 61 CFTR modulators may alter the gut microbiota composition to resemble that of healthy individuals more 62 closely, alongside improving other common intestinal abnormalities and symptoms in pwCF.

63 Previous studies investigating CFTR modulators and microbiota within the gastrointestinal tract have 64 been mostly limited to lvacaftor [15-18] and a couple of dual-modulator studies [17], including our previous work investigating the impact of Tezacaftor/Ivacaftor [19]. With respect to the microbiota 65 66 structure, previous findings vary across studies incorporating different modulators, patient 67 demographics, and treatment lengths [15–18]. Results for the frequently observed inflammation in the gut following modulator treatment are also contrasting. Some studies observed a reduction in faecal 68 69 calprotectin following modulator usage [15,20,21], whilst others [16] and our own group [19], did not 70 measure any notable reduction.

Following the approval of Elexacaftor/Tezacaftor/Ivacaftor (ETI) triple modulator therapy for pwCF from NHS England, over 60% of all pwCF in the United Kingdom are now registered users [3]. ETI therapy demonstrates increased clinical efficacy as compared to previous dual or mono-therapy approaches [22], yet little information is available on intestinal outcomes and the impact upon the gut microbiota.

75 Given the scarcity of current evidence, the aim of this pilot study was to therefore assess the impact of 76 ETI therapy in pwCF upon the intestinal microbiota. We characterised the respective gut microbiota of 77 pancreatic insufficient pwCF  $\geq$  12 years, with at least one copy of the F508del mutation, before and 78 during ETI therapy of up to 23 months duration. Furthermore, we combined microbiota data with 79 targeted metabolomics of quantified faecal short-chain fatty acids (SCFAs), patient clinical data, and 80 markers of intestinal function as measured by magnetic resonance imaging (MRI) [23]. Patient 81 symptoms were also measured before and after initiating ETI therapy. Samples and clinical data from 10 matched healthy controls were available for analysis. We hypothesised that ETI therapy would 82 83 increase gut microbiota diversity, reshape community structure, and potentially lead to functional 84 changes to resemble outcomes measured in healthy controls.

85

#### 86 2. Methods

# 87 2.1. Study participants and design

88 Twenty-four pwCF were initially recruited from Nottingham University Hospitals NHS Trust, with 20 89 participants ultimately providing at least one faecal sample following ETI therapy to form the cohort for 90 our observational study. Participants attended clinic at baseline, 3, and 6 months following the initiation 91 of ETI. A subset of pwCF (n = 7) also provided samples following extended ETI therapy of 19.8 ± 2.0 92 months (mean ± SD), with a minimum time of 17 months additional treatment. Additional faecal samples 93 and metadata for 10 age and sex-matched healthy controls from our previous study were available for 94 microbiota and metabolomic comparison also [24]. During study visits, participants provided faecal 95 samples and completed magnetic resonance imaging (MRI) scans following the consumption of a 96 standardised meal plan to detail their gut function as conducted previously [24], alongside specifying 97 gut symptoms. This included the validated PAC-SYM questionnaire [25]. The full study design, including 98 protocols, methods, and other results are described in the Supplementary Methods & Results. An 99 overview of participant clinical characteristics is detailed in Table 1, with comprehensive participant 100 information and MRI data detailed in Tables S1 and S2, respectively. Access to the MRI data 101 (unpublished) was kindly granted by the University of Nottingham MRI research team at the Sir Peter 102 Mansfield Imaging Centre. Written informed consent, or parental consent and assent for paediatric 103 participants, was obtained from all participants. Study approval was obtained from the UK National

104 Research Ethics Committee (20/PR/0508). All faecal samples obtained were immediately stored at 105 80°C prior to processing for microbiota sequencing and metabolomics to reduce changes before
106 downstream community analysis [26].

107

108 2.2. Targeted amplicon sequencing

109 DNA from dead or damaged cells, as well as extracellular DNA was excluded from analysis via cross-110 linking with propidium monoazide (PMA) prior to DNA extraction, as previously described [27]. Cellular pellets resuspended in PBS were loaded into the ZYMO Quick-DNA Fecal/Soil Microbe Miniprep Kit 111 112 (Cambridge Bioscience, Cambridge, UK) as per the manufacturer's instructions. Dual mechanical-113 chemical sample disruption was performed using the FastPrep-24 5G instrument (MP Biomedicals, 114 California, USA). Following DNA extraction, approximately 20 ng of template DNA was then amplified 115 using Q5 high-fidelity DNA polymerase (New England Biolabs, Hitchin, UK) using a paired-end 116 sequencing approach targeting the bacterial 16S rRNA gene region (V4-V5) as previously described 117 [24]. Pooled barcoded amplicon libraries were sequenced on the Illumina MiSeq platform (V3 118 Chemistry). Extended methodology, primers and PCR conditions can be found in the Supplementary 119 Methods & Results.

120

## 121 2.3. Sequence processing and analysis

Sequence processing and data analysis were then carried out in R (Version 4.2.1), utilising the packages DADA2 [28] and decontam [29]. The full protocol is detailed in the Supplementary Methods & Results. Raw sequence data reported in this study has been deposited in the European Nucleotide Archive under the study accession number PRJEB61286.

126

127 2.4 Gas-chromatography mass-spectrometry (GC-MS) of faecal samples to investigate SCFA levels.

GC-MS analysis was carried out using an Agilent 7890B/5977 Single Quadrupole Mass Selective
Detector (MSD) (Agilent Technologies) equipped with a non-polar HP-5ms Ultra Inert capillary column
(30 m × 0.25 mm × 0.25 µm) (Agilent Technologies). Faecal sample processing to obtain, and then to
derivatise SCFAs prior to GC-MS analysis, was carried out as previously described [19]. Following
derivatisation, samples were loaded onto the GC-MS and injected using an Agilent 7693 Autosampler.
MS grade water processed in parallel was used as a blank sample to correct the background. Selected

ion monitoring (SIM) mode was used for subsequent analyses; all confirmation and target ions lists are
summarised in Table S3. Agilent MassHunter workstation version B.07.00 programs were used to
perform post-run analyses. A <sup>13</sup>C-short chain fatty acids stool mixture (Merck Life Science, Poole, UK)
was used as the internal standard to normalise all spectra obtained prior to analyses. A volatile fatty
acid mixture (Merck Life Science, UK) was used to construct calibration curves for the quantification of
target metabolites. Extended information surrounding sample processing, SCFA extraction,
derivatisation, and GC-MS parameters can be found in the Supplementary Methods & Results.

141

### 142 2.5. Faecal Calprotectin measurement

Stool was extracted for downstream assays using the ScheBo® Master Quick-Prep (ScheBo Biotech,
Giessen, Germany), according to the manufacturer instructions. Faecal calprotectin was analysed using
the BÜHLMANN fCAL ELISA (Bühlmann Laboratories Aktiengesellschaft, Schonenbuch, Switzerland),
according to the manufacturer's protocol.

147

# 148 2.6. Statistical Analysis

149 Regression analysis, including calculated coefficients of determination ( $r^2$ ), degrees of freedom (df), F-150 statistic and significance values (P) were utilised for microbial partitioning into common core and rarer 151 satellite groups, and were calculated using XLSTAT v2021.1.1 (Addinsoft, Paris, France). Fisher's 152 alpha index of diversity and the Bray-Curtis index of similarity were calculated using PAST v3.21 [30]. 153 Tests for significant differences in microbiota diversity and SCFAs were performed using Kruskal-Wallis 154 in XLSTAT. Student's t-tests used to determine differences in metadata were also performed in 155 XLSTAT. Analysis of similarities (ANOSIM) with Bonferroni correction was used to test for significance 156 in microbiota and SCFA composition and was performed in PAST. Similarity of percentages (SIMPER) 157 analysis, to determine which constituents drove compositional differences between groups, and was 158 performed in PAST. Redundancy analysis (RDA), was performed in CANOCO v5 [31]. Statistical 159 significance for all tests was deemed at the  $P \le 0.05$  level.

<b>I able 1.</b> Overall clinical characteristics of controls and pwCF at baseline.					
Characteristic	pwCF	Controls			
Baseline Age (Mean ± SD)	21.0 ± 8.6	21.4 ± 7.4			
Male (%)	15 (75)	5 (50)			
Baseline BMI (Mean ± SD)	21.1 ± 3.4	$22.9 \pm 4.4$			
F508del/F508del (%)	13 (65)	0 (0)			
Baseline FEV1% (Mean ± SD)	79.1 ± 20.5	-			
Pancreatic insufficient (%)	20 (100)	0 (0)			
Cystic fibrosis-related diabetes (%)	4 (20)	-			
Antibiotics during study (%)	14 (70)	0 (0)			

161

162

#### 3. Results 163

164 Following sequence processing and taxa assignment, the microbiota data across each pwCF treatment period from baseline, and the healthy control participants was partitioned for further sub-analysis. 165 166 Microbiota data were partitioned into common abundant core taxa, and rarer less frequent satellite taxa 167 following the establishment of significant distribution abundance relationships of the taxa across all 168 treatment duration groups and the healthy control participants (Figure S1). The core taxa (Table S4) 169 constituted 70.1 % of the total abundance for the healthy controls, whilst across pwCF they averaged 170 30.0% ± 6.1 (Mean ± SD).

171 Diversity of the whole microbiota, core taxa, and satellite taxa was plotted across the increasing ETI 172 treatment periods in pwCF (Figure 1A). Overall, the diversity changes across all microbiota partitions included a gradual decline until 6 months of ETI treatment, highlighted by the significant reduction in 173 174 diversity between baseline and 6 months for the whole microbiota (P = 0.001), core taxa (P = 0.003), and satellite taxa (P = 0.001) (Table S5). This was then succeeded by an increase in diversity following 175 176 extended ETI treatment. The most pronounced change was the core taxa, for which diversity greatly 177 increased following extended ETI treatment relative to other time points, reflected by significant increases in diversity compared to both baseline (P = 0.001) and the 6-month time period (P < 0.001) 178 179 (Table S5). Despite the positive trajectory of diversity in pwCF following extended ETI therapy, there 180 remained distinct differences when compared to healthy controls (Figure 1B, Table S6), whereby all 181 partitions of the microbiota were significantly more diverse as compared to pwCF (P = 0.001).



182

183 Figure 1. Microbiota diversity compared across groups utilising Fisher's alpha index of diversity. Black plots 184 indicate the whole microbiota, whilst orange and grev denote the core and satellite taxa respectively. (A) Diversity 185 across pwCF at baseline or following ETI treatment. Black circles denote individual patient participant data. Error 186 bars represent 1.5 times the inter-quartile range (IQR). Blue line indicates trend and direction of travel through the 187 median of each treatment time point. Asterisks denote significant differences in diversity between treatment periods 188 (sequential and to baseline) following Kruskal-Wallis testing (Table S5). (B) Diversity of pwCF and also healthy 189 controls for comparison. Black circles denote individual patient participant data. Error bars represent 1.5 times the 190 inter-quartile range (IQR). Asterisks denote significant differences in diversity between pwCF treatment periods 191 and healthy controls following Kruskal-Wallis testing (Table S6). Abbreviations; 0,3 & 6 - Samping time point 192 (months), 17+ – Extended (17+ months) sampling period, HC – Healthy control participants. P values; \*\*\*; P ≤ 193 0.0001, \*\*; P  $\leq 0.001$ , \*; P  $\leq 0.05$ .

194

When analysing microbiota composition throughout ETI treatment, similarity of the whole microbiota 195 196 composition increased in pwCF as ETI treatment progressed, with a mean similarity ( $\pm$  SD) of 0.32  $\pm$ 197 0.09 following extended ETI (Figure 2A). Within-group similarity did however remain larger in the healthy 198 controls, with a mean similarity of 0.44 ± 0.06. Within-group similarity for the satellite taxa initially 199 increased but was relatively consistent throughout ETI treatment and was comparable to healthy 200 controls following extended ETI (0.19  $\pm$  0.04 and 0.19  $\pm$  0.07, respectively). The core taxa similarity, 201 however, increased in pwCF following extended ETI, surpassing that of healthy control participants 202  $(0.60 \pm 0.12 \text{ and } 0.57 \pm 0.06, \text{ respectively})$ . When comparing the composition of the microbiota between 203 sequential ETI treatment periods (Figure 2B), the largest similarity across the whole microbiota and 204 core taxa could be observed between 6 months and the extended ETI period, whilst the satellite taxa 205 had no clear direction of travel. There were, however, significant differences between both the core (P

206 < 0.001) and satellite (P = 0.035) taxa between months 3 and 6 of ETI treatment (Table S7). When</p>
207 comparisons were extended to include healthy controls (Figure 2C), all partitions of the microbiota in
208 pwCF illustrated the highest resemblance to healthy controls following the extended ETI treatment
209 period. Regardless of this increased similarity, microbiota composition of the healthy controls remained
210 highly distinct and significantly different (P < 0.001) from pwCF throughout the study period (Figure 2C,
211 Table S8).

212



# 213

# Treatment lengths/group

Figure 2. Microbiota similarity compared across groups utilising the Bray-Curtis index of similarity. (A) Within group similarity across pwCF at baseline or following ETI treatment, and healthy controls. (B) Between group similarity change over time in pwCF. (C) Similarity between pwCF on ETI at various time points and healthy control participants. Error bars represent standard deviation of the mean. Asterisks inicate significant differences in microbiota composition following the use of one-way ANOSIM testing. Summary statistics are presented in Tables S7-8. *P* values; \*\*\*; P ≤ 0.0001, \*\*; P ≤ 0.001, \*; P ≤ 0.05.

221 To understand which taxa were driving the dissimilarity maintained between healthy control participants

and pwCF following extended ETI therapy, SIMPER analysis was conducted (Table 2). The top drivers

of dissimilarity between the groups were *Blautia* sp. (OTU 1), *Bifidobacterium adolescentis*, *Bacteroides* 

224 dorei, Eubacterium rectale, and Anaerostipes hadrus. Overall, 24 taxa comprised over 50% of the

dissimilarity between the groups and this consisted of many prominent SCFA producing bacteria from

226 other genera, including Faecalibacterium, Ruminococcus, and Collinsella, Interestingly, some of these

taxa were increased in the pwCF group compared to the healthy controls. Additional SIMPER analysis

between baseline and following extended ETI therapy revealed that similar taxa were also drivers of
the change seen across the ETI treatment period in pwCF (Table S9).

230 To investigate the relationships between participant clinical variables and microbiota composition, 231 redundancy analysis (RDA) was performed. Within comparisons between pwCF following extended ETI 232 and the healthy control participants (Table 3), whole microbiota variability was explained by (in 233 ascending order) the presence of CF disease, antibiotic usage, and age. For the core taxa analysis, CF 234 disease was the primary driver of variation, with sex also contributing. CF disease was also the main 235 contributor of variation in the satellite taxa, followed by antibiotic usage and patient small bowel water 236 content (SBWC). When relating variability of the microbiota solely within pwCF (from baseline to 237 extended ETI) (Table S10), multiple variables significantly explained the variation in the whole 238 microbiota, including disease severity (FEV1%), BMI, antibiotic usage, sex, and SBWC. Excluding BMI, 239 these variables also significantly explained variation across the core taxa. For the satellite taxa analysis, 240 Age and ETI treatment length also significantly explained some of the variation. Species RDA biplots 241 were then plotted to visualise how the taxa driving differences across pwCF and controls related to 242 significant clinical variables identified from the RDA approach. Between the healthy controls and pwCF 243 on extended ETI (Figure 3), a group of taxa containing Faecalibacterium and Bacteroides members 244 collectively clustered strongly away from CF disease and the usage of antibiotics, whilst taxa such as 245 Blautia sp. (OTU 1), Ruminoccocus gnavus, Enterococcus sp. (OTU 26), and Eubacterium hallii 246 demonstrated the opposite trend. Some taxa were explained primarily by both participant age and sex. 247 This included Blautia luti, Dorea longicatena, Holdemanella biformis, Bacteroides dorei, Escherichia 248 coli, and Bifidobacterium adolescentis. In terms of SBWC, this explained the variation across a group 249 of taxa including Fusicatenibacter saccharivorans and Gemmiger formicilis. Within pwCF exclusively 250 (baseline to extended ETI), different taxa and variables comprised the RDA biplot due to outcomes from 251 the previous SIMPER and RDA analyses (Figure S2). Some similar trends were observed however, 252 including the strong association of *Enterococcus* sp. (OTU 24) with antibiotic usage and *Blautia* sp. 253 (OTU 1) away from more mild CF disease.

% Relative abundance						
_	17+	Healthy	Av.	%	Cumulative	
Таха	Months	Controls	Dissimilarity	Contribution	(%)	
Blautia 1 Bifidobacterium	11.70	4.91	3.24	4.53	4.53	
adolescentis	4.90	0.81	2.35	3.28	7.81	
Bacteroides dorei	3.79	3.35	2.12	2.95	10.77	
Eubacterium rectale	3.68	4.78	2.02	2.82	13.58	
Anaerostipes hadrus Fusicatenibacter	4.35	1.99	2.00	2.79	16.37	
saccharivorans	5.73	3.69	1.96	2.74	19.11	
Ruminococcus bromii	3.34	2.93	1.93	2.70	21.81	
Gemmiger formicilis	4.24	1.05	1.90	2.65	24.46	
Blautia luti	5.55	3.01	1.63	2.27	26.73	
Bacteroides vulgatus	1.66	3.32	1.62	2.26	28.99	
Collinsella aerofaciens	3.33	0.19	1.59	2.23	31.21	
Dorea longicatena	4.39	1.79	1.47	2.05	33.26	
Eubacterium hallii	4.81	2.39	1.26	1.76	35.02	
Escherichia coli	2.27	1.99	1.26	1.76	36.78	
Blautia obeum	0.98	2.51	1.15	1.61	38.38	
Ruminococcus gnavus	2.48	0.04	1.13	1.58	39.96	
Bacteroides uniformis	0.14	2.55	1.11	1.55	41.51	
Holdemanella biformis	2.01	0.45	1.09	1.52	43.03	
Blautia faecis	2.12	2.30	0.98	1.38	44.40	
Faecalibacterium duncaniae	2.09	2.15	0.98	1.37	45.78	
Enterococcus 26	2.07	0.31	0.98	1.37	47.15	
Faecalibacterium longum	0.42	2.19	0.96	1.35	48.49	
Ruminococcus faecis	2.27	1.61	0.96	1.34	49.84	
Faecalibacterium prausnitzii	0.00	2.04	0.95	1.32	51.16	

**Table 2**. Similarity of percentage (SIMPER) analysis of microbiota dissimilarity (Bray-Curtis)

 between healthy control and pwCF samples following 17+ months (extended) treatment with ETI.

Taxa identified as core are highlighted in orange, with satellite taxa highlighted in grey. The mean relative abundance (%) across both groups is given, alongside the percentage contribution which is the mean dissimilarity of taxa divided by the mean dissimilarity (71.26%) across samples. Cumulative percent does not equal 100% as the list is not exhaustive, rather the taxa that make up 50% of dissimilarity between groups. Given the length of the 16S gene regions sequenced, taxon identification should be considered putative.

Table 3. Redundancy analysis to explain percent variation across whole microbiota, core, and
satellite taxa of the significant clinical variables across healthy control participants and pwCF
receiving 17+ months (extended) ETI therapy.

	Microbiota			Core taxa			Satellit	Satellite taxa	
	Var. Exp (%)	pseudo- <i>F</i>	P (adj)	Var. Exp (%)	pseudo- <i>F</i>	P (adj)	Var. Exp (%)	pseudo- <i>F</i>	P (adj)
Age	10.1	2.0	0.008						
Antibiotics	10.6	2.0	0.018				10.8	1.9	0.012
CF Disease	13.3	2.3	0.002	27.5	5.7	0.002	16.0	3.3	0.002
SBWC							10.8	1.8	0.050
Sex				10.0	2.2	0.028			
Total	23.9			37.5			37.6		

261

262 Both the composition and absolute quantification of SCFAs from pwCF and healthy control samples 263 were also investigated (Figure S3). Combined, the relative abundance of acetic, propionic, and butyric 264 acid accounted for the vast majority of SCFAs across both the pwCF ETI treatment periods (94.0% ± 265 4.5, Mean ± SD) and healthy controls (89.6% ± 4.8, Mean ± SD). There were no significant differences 266 from baseline, or subsequent sampling periods, in the absolute concentration or relative abundance of SCFAs across pwCF receiving ETI therapy (Figure S3, Tables S11-12). There were, however, 267 268 significant differences between ETI samples and healthy controls (Figure S3, Table S13-14). This 269 included significant increases in both absolute concentration and relative abundance of valeric (Figure 270 S3 A&C) and heptanoic acid (Figure S3 B&D) within healthy control samples compared with all ETI 271 sampling periods (P < 0.05 in all instances), with hexanoic acid also significantly increased compared 272 to pwCF, except those on extended ETI (P = 0.143) (Figure S3 B&D). On the contrary, the only 273 significantly increased SCFA in pwCF was butyric acid, with significantly higher concentrations 274 measured during the extended ETI sampling period as compared to health controls (P = 0.015) (Figure 275 S3A).

276 The overall composition of SCFAs remained similar in pwCF throughout ETI therapy but remained 277 significantly different from healthy controls during both the 6 months and extended ETI therapy periods (P < 0.05 in all instances) (Table S15). Over 50% of this dissimilarity was driven by acetic and butyric 278 279 acid in both cases (Table S16). Exploratory RDA revealed that only a few SCFA, namely propionic, 280 butyric, and valeric acid could significantly explain any variation across the microbiota composition 281 across all samples, and to a minimal extent (Table S17). RDA biplots were constructed to visualise the 282 relationships between SIMPER taxa and these SCFAs within both pwCF and healthy controls (Figure

283 S4). Results were mixed, with high variability across particular genera, including Bacteroides, Blautia,

284 Ruminococcus, whilst others such as Faecalibacterium and Eubacterium behaved similarly and were

- 285 more closely clustered. Other taxa were strongly dissociated with the SCFAs from the RDA biplot model,
- including Blautia spp. (OTU 1) and Fusicatenibacter saccharivorans.



287

288 Figure 3. Redundancy analysis species biplots for the whole microbiota. The 24 taxa contributing most to the 289 dissimilarity (cumulatively > 50%) between healthy control and pwCF samples following extended ETI therapy from 290 the SIMPER analysis (Table 2) are shown independently of the total number of ASVs identified (531). Orange 291 points represent taxa that were identified as core for the pwCF group following extended ETI therapy, grey points 292 are satellite, and the white (black stroke) points represent taxa that were absent. Biplot lines depict clinical variables 293 that significantly account for total variation in taxa relative abundance within whole microbiota analysis at the  $p \leq p$ 294 0.05 level (Table 3). Species plots depict the strength of explanation provided by the given clinical variables, with 295 taxa shown in the same direction of a particular clinical variable considered to have a higher value than those that are not. 'Abx' - Antibiotics during sampling period, 'SBWC' - Small bowel water content corrected for body surface 296 297 area. The percentage of microbiota variation explained by each axis is given in parentheses.

- 299 Finally, when comparing symptoms and gut function across pwCF and healthy controls, it was evident
- 300 that ETI therapy did not significantly improve PAC-SYM scores irrespective of treatment length (P >
- 301 0.05 in all instances) (Table S18). In terms of functionality, no significant differences in oro-caecal transit
- 302 time (OCTT) (P = 0.842) or SBWC (P = 0.064) between pwCF in this cohort undergoing microbiota
- 303 analyses and healthy controls occurred, however the latter was markedly increased (Table S19).

#### 305 4. Discussion

306 As the efficacy of CFTR modulators continues to increase in alleviating respiratory complications of CF, 307 there is need to clarify whether patient improvements further translate at the site of the intestinal tract. 308 This includes both GI abnormalities and patient symptoms following CFTR modulator treatment, 309 including the effects upon the gut microbiota, for which data remain scarce and to the best of our 310 knowledge has not been characterised in pwCF following ETI therapy. Here we examined the impact 311 of ETI on the gut microbiota and their associated metabolites, utilising 16S rRNA sequencing and 312 integrated targeted metabolomics to profile and quantify faecal levels of short-chain fatty acids. Overall, 313 our results indicate that ETI therapy does impact upon microbiota structure in pwCF, but this remains 314 distinctly different to that of healthy control participants as observed previously [8,32,33].

315 With respect to microbiota diversity, we demonstrate a significant shift in the core taxa of pwCF following 316 extended ETI therapy, which translated into a positive trajectory of whole microbiota diversity by the 317 end of the study period. Despite this, diversity was not significantly different following ETI, as shown 318 previously with less efficacious CFTR modulator treatments encompassing shorter administration 319 periods [15–17,19]. Interestingly, Kristensen et al. did observe significant increases in faecal microbiota 320 diversity [18], but only following extended (12 month) Ivacaftor therapy in a group of pwCF harbouring 321 the S1251N mutation. Unlike others [15–17,19], they also found that microbiota composition changed 322 significantly over time, with samples obtained following extended lvacaftor more tightly clustered [18]. 323 In the current study, the core taxa and whole microbiota became more similar in pwCF as ETI 324 progressed, also increasing in similarity to healthy controls. There remained, however, a significant 325 difference in microbiota composition to controls as previously observed throughout life in pwCF [7-326 9,24].

The significant difference in microbiota composition maintained between pwCF and controls following extended ETI was driven by taxa previously associated with SCFA production in the gut, including members of the genera *Faecalibacterium*, *Eubacterium*, and *Blautia* [34,35]. Across pwCF specifically, *Faecalibacterium* remained a satellite taxa constituent and did not substantially contribute to any changes in the community from baseline, whilst relative abundances of *Eubacterium* were generally increased, and *Blautia* species fluctuated over the treatment period in pwCF. This raises the possibility of increased fitness and subsequent proliferation of particular taxa following altered intestinal fluidity

334 subsequent to CFTR modulation, alongside decreased susceptibility to additional CF-associated 335 perturbations that typically impacts the rarer satellite taxa. When incorporating targeted metabolomics to understand any functional changes relating to the aforementioned taxa, we identified no key 336 337 differences in pwCF following ETI treatment, further extending with healthy controls for acetic, propionic, 338 isobutyric, butyric and isovaleric acid. These findings are in agreement with Baldwin-Hunter et al., who 339 recently analysed colonic aspirates from adult pwCF and controls undergoing surveillance colonoscopy 340 [36]. Collectively, this may support elements of functional redundancy surrounding major SCFA production in the distal colon in pwCF [37], and is further supported by the low microbial variation 341 342 explained here by faecal SCFA levels when both pwCF and control samples were collated. In contrast, 343 Vernocchi et al. did demonstrate significant reductions in major SCFAs across children with CF as 344 compared to controls [38], which raises the possibility of age-dependent functional redundancy. Similar 345 to Baldwin-Hunter et al. again [36], both valeric and hexanoic acid concentration and relative 346 abundances were significantly larger in healthy control participants compared to pwCF. Furthermore, 347 valeric acid did significantly explain variation in the microbiota across all samples collated for analysis, 348 with those associated taxa typically satellite members of the microbiota in pwCF. Any potential 349 implications of this remain to be clarified in CF as valeric and hexanoic acid have previously been shown 350 to significantly decrease within intestinal pro-inflammatory environments as compared to healthy 351 controls [39].

352 Furthering our analyses to reveal any relationships between clinical data, gut function, and microbiota 353 structure across participants, we observed a strong impact of CF disease, antibiotic exposure, and age 354 upon microbiota composition similar to our previous work [24]. CF disease was the primary explanator 355 of the core taxa, which is unsurprising given the strong associations between CFTR genotype alone 356 and gut microbiota composition [11]. Alongside the whole microbiota, antibiotic usage was a principal explanator of satellite taxa composition across participants, again underpinning the relevance of this 357 358 partitioned community towards wider microbiota organisation and structure. Within the exclusive 359 analysis of pwCF, antibiotic usage was a prominent explanator of the bacterial community across all 360 partitions, second only to age within the satellite taxa analysis and explaining more variance than CF 361 disease severity and treatment length of ETI. Indeed, antibiotics have previously been shown to significantly impact community composition across pwCF also taking CFTR modulators, to which the 362 363 latter had relatively little impact [17]. Given the speculated systemic impact of pulmonary antibiotics in-

364 turn affecting the gut microbiota [8,24,38,40,41], it still remains in question whether this will persist 365 following sustained CFTR modulator therapy that commences earlier in life across pwCF [42]. In this cohort, not all participants were undertaking antibiotic therapy, including those on extended ETI. Of the 366 367 pwCF that were administered antibiotics however, levels of exposure were at least maintained during 368 the extended ETI period. Gut function also continues to explain the microbiota variance across pwCF 369 and controls [24]. SBWC was not significantly altered following ETI treatment and remains elevated 370 across pwCF [23], significantly explaining the satellite taxa composition across all participants in this 371 study. The physiological mechanisms behind this increased SBWC are proposed to result from gastro-372 ileal abnormalities in CF [43], including delayed ileal-emptying of small bowel content which might have 373 consequences for downstream taxa in the large intestine.

374 Relating bacterial taxa from our SIMPER analysis with principal drivers of microbiota variation 375 determined by the RDA approach revealed associations across species both typically identified as 376 favourable and adverse to the host with CF disease and antibiotic usage. This included Blautia spp. 377 and Eubacterium hallii which contain the functional capacity for anti-inflammatory butyrate synthesis 378 from a range of substrates [44], but also Enterococcus spp. and Ruminococcus gnavus, which have 379 both been shown to be increased in the CF gut and associate with intestinal inflammation [9,45,46], 380 perhaps indicative of acquired resistance to recurrent antibiotic regimens in CF [47]. Within pwCF 381 specifically, the relationships between disease severity (determined by FEV1%) and intestinal microbial 382 composition may suggest the need to further understand the putative lung-gut axis in CF [6,48,49]. The 383 implications of any taxa change upon host immunology at the site of the intestinal tract remains to be 384 clarified and moving forward will be aided by the thorough integration of faecal and local intestinal 385 inflammatory data. Across all participants, age and sex were also explanators of the whole microbiota 386 and core taxa respectively, associating with taxa such as Escherichia coli and Bifidobacterium 387 adolescentis. This may be explained in part by the ratio of males to females, alongside the wide age 388 range of our participants, with the relative abundance of the aforementioned impacted by age across 389 both CF and general life [40,50-52].

Alongside the microbiota analyses, it was evident that patient symptoms, as measured by overall PAC-SYM scores, were not improved upon treatment with ETI. This is consistent with our previous cohort undertaking Tezacaftor/Ivacaftor therapy [19], yet Mainz et al. have recently described improvements

within pwCF GI symptoms upon ETI therapy when utilising the tailored CFAbd questionnaire [53].
Intestinal inflammation is a common occurrence in pwCF [54–56]. Unfortunately, we were unable to
incorporate faecal calprotectin data into this study due to limited measurement across participants.
Previous modulator studies have reported mixed results in the reduction of faecal calprotectin
[16,57,58]. However, with ETI therapy specifically, there is evidence of a reduction following 6 months
of administration [59].

Collectively, our microbiota findings indicate a positive impact of ETI therapy upon core taxa and whole 399 400 microbiota structure in pwCF. The significant differences that persist between the CF and healthy 401 control microbiota suggests changes are further required across the CF satellite taxa to bridge this gap, 402 which make up a significant portion of the relative community abundance [24], and are typically related 403 to random environmental perturbations or atypical habitats [60,61]. Based on this, the modulation of CFTR alone may not be sufficient to rescue a microbiota signature observed across controls within 404 405 pwCF, whereby the modulation of such alternate clinical factors primarily explaining the satellite taxa 406 composition may be also required for an enhanced response to CFTR modulator therapy. This 407 encompasses pulmonary antibiotic usage, which was a key explanator across our multivariate analyses 408 and of high prevalence across pwCF undertaking extended ETI. Though not investigated in the current 409 study, additional research into the ability of specific dietary intake and probiotic usage to shape the 410 microbiota and patient outcomes is desirable [62-64], especially since resilience of the gut microbiota 411 has been recently suggested following diet and exercise intervention in pwCF [65]. It could be that long-412 term substantial changes to such factors are necessary for subsequent beneficial changes to the 413 intestinal microbiome in an era of modulator therapy.

414 Comprehensively understanding the impact of more efficacious CFTR modulator therapy itself remains 415 a top research priority in CF, including the identification of novel compounds or biomarkers to enhance 416 our understanding of disease management [66,67]. The latter is likely to be aided by continued 417 integration of additional omics techniques to fully elucidate not only the genetic potential, but 418 measurable functional alterations upon CFTR modulator usage and changes to the CF lifestyle. This should include the impact of pulmonary antibiotic towards CF intestinal metabolomic and/or 419 420 metaproteomic signatures, given their common, persistent use in clinic and at home. This may extend 421 further to the utilisation of model experimental systems [68], which with tighter experimental control will

422 aid our future understanding of the aforementioned. Aside from the clear caveat of group size in our 423 pwCF cohort receiving extended ETI therapy, we acknowledge the relatively large sampling gap 424 between this period and the preceding sampling point of 6 months within this pilot study. Nonetheless, 425 our extended sampling period highlights the value of further understanding alternate factors to the sole 426 presence of disease in altering the CF microbiota, patient symptoms and intestinal abnormalities, as 427 treatment with CFTR modulators alone may not be optimal to achieve this goal in CF.

# 428 5. Conclusion

429 In conclusion, we have demonstrated that ETI therapy in pwCF does lead to change in microbiota 430 characteristics towards that observed in healthy controls following extended administration, albeit with 431 negligible difference upon SCFA levels and other clinical outcomes. Collectively the composition of the 432 microbiota and functional metabolites remained significantly different from healthy controls following 433 extended therapy. We posit that the trajectory of the CF gut microbiota towards that observed in the 434 healthy controls was predominately impeded by antibiotics administered to combat respiratory infection. 435 We recommend future work should employ a combination of frequent/prolonged patient cohort studies 436 and experimental model system approaches to gain a deeper mechanistic understanding of the effects 437 of both the CFTR modulator therapies and pulmonary antibiotics on the temporal dynamics of gut 438 microbiota composition functioning. In turn this could then be related to alleviating and improving 439 abnormalities of the intestinal tract and patient symptoms in CF.

#### 440 Author contributions

441 CvdG, DR, ARS, GM, and RM conceived the microbiome study. RM, and LH performed microbiota 442 sample processing and analysis. RM and CDS carried out the metabolomic analysis. RM, DR, and 443 CvdG performed the data and statistical analysis. AY, ND, CH, CN, GM, and AS were responsible for 444 sample collection, clinical data collection, care records, and documentation. RM, AY, and CvdG 445 verified the underlying data. RM, DR, and CvdG were responsible for the creation of the original draft 446 of the manuscript. RM, GM, DR, ARS, and CvdG contributed to the development of the final 447 manuscript. CvdG is the guarantor of this work. All authors read and approved the final manuscript.

448

# 450 Funding

- 451 This work was funded by CF Trust grant (VIA 77) awarded to CvdG and DWR. The wider 'Gut Imaging
- 452 for Function & Transit in Cystic Fibrosis Study 3' (GIFT-CF3) was supported with funding from a Cystic
- 453 Fibrosis Trust grant (VIA 061), a Cystic Fibrosis Foundation award (Clinical Pilot and Feasibility Award
- 454 SMYTH18A0-I), and a Vertex Pharmaceuticals Investigator-Initiated Study award (IIS-2018-106697).

# 455 Declaration of Competing Interest

- 456 RM, CDS, ND, and CH have nothing to disclose. DR and CvdG report grant funding from Vertex
- 457 Pharmaceuticals outside of the submitted work. AY, CN, GM, and ARS report grants and speaker
- 458 honorarium from Vertex Pharmaceuticals outside the submitted work.

# 459 Acknowledgements

- 460 We would like to thank Neele Dellschaft, Caroline Hoad, Luca Marciani, and Penny Gowland of the
- 461 Sir Peter Mansfield Imaging Centre, University of Nottingham, who acquired the original MRI data for
- 462 healthy control participants [23].

#### 464 References

- S. Smith, N. Rowbotham, G. Davies, K. Gathercole, S.J. Collins, Z. Elliott, S. Herbert, L. Allen, 465 [1] 466 C. Ng, A. Smyth, How can we Relieve Gastrointestinal Symptoms in people with Cystic 467 Fibrosis? An International Qualitative Survey, BMJ Open Respir. Res. 7 (2020) e000614. 468 https://doi.org/10.1136/bmjresp-2020-000614.
- 469 [2] M. Lopes-Pacheco, CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of 470 Precision Medicine, Front. Pharmacol. 10 (2020) 1662. https://doi.org/10.3389/fphar.2019.01662. 471
- 472 Cystic Fibrosis Trust, UK Cystic Fibrosis Trust, UK Cystic Fibrosis Registry. 2022 Annual Data [3] 473 Report, London, 2023.
- 474 [4] Cystic Fibrosis Refresh Top 10 priorities (priority setting in association with the JLA), (2022). 475 https://www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis-refresh/top-10-476 priorities.htm.
- 477 N.J. Rowbotham, S. Smith, Z.C. Elliott, B. Cupid, L.J. Allen, K. Cowan, L. Allen, A.R. Smyth, A [5] 478 Refresh of the Top 10 Research Priorities in Cystic Fibrosis, Thorax. 78 (2023) 840-843. 479 https://doi.org/10.1136/thorax-2023-220100.
- 480 J.C. Madan, D.C. Koestle, B.A. Stanton, L. Davidson, L.A. Moulton, M.L. Housman, J.H. [6] Moore, M.F. Guill, H.G. Morrison, M.L. Sogin, T.H. Hampton, M.R. Karagas, P.E. Palumbo, 481 482 J.A. Foster, P.L. Hibberd, G.A. O'Toole, Serial Analysis of the Gut and Respiratory 483 Microbiome, MBio. 3 (2012) e00251-12. https://doi.org/10.1128/mBio.00251-12.Editor.
- 484 [7] M.J. Coffey, S. Nielsen, B. Wemheuer, N.O. Kaakoush, M. Garg, B. Needham, R. Pickford, A. 485 Jaffe, T. Thomas, C.Y. Ooi, Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and 486 Functional Dysbiosis, Sci. Rep. 9 (2019) 18593. https://doi.org/10.1038/s41598-019-55028-7.
- 487 [8] D.G. Burke, F. Fouhy, M.J. Harrison, M.C. Rea, P.D. Cotter, O.O. Sullivan, C. Stanton, C. Hill, 488 F. Shanahan, B.J. Plant, R.P. Ross, The Altered Gut Microbiota in Adults with Cystic Fibrosis, 489 BMC Microbiol. 17 (2017) 58. https://doi.org/10.1186/s12866-017-0968-8.
- 490 [9] M. Kristensen, S.M.P.J. Prevaes, G. Kalkman, G.A. Tramper-Stranders, R. Hasrat, K.M. de 491 Winter- de Groot, H.M. Janssens, H.A. Tiddens, M. van Westreenen, E.A.M. Sanders, B. 492 Arets, B. Keijser, C.K. van der Ent, D. Bogaert, Development of the Gut Microbiota in Early 493 Life: The Impact of Cystic Fibrosis and Antibiotic Treatment, J. Cyst. Fibros. 19 (2020) 553-494 561. https://doi.org/10.1016/j.jcf.2020.04.007.
- 495 [10] D. Debray, H. El Mourabit, F. Merabtene, L. Brot, D. Ulveling, Y. Chrétien, D. Rainteau, I. Moszer, D. Wendum, H. Sokol, C. Housset, Diet-Induced Dysbiosis and Genetic Background 496 497 Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to 498 Promote Cholangiopathy in Mice, Hepatol. Commun. 2 (2018) 1533–1549. 499 https://doi.org/10.1002/hep4.1266.
- 500 [11] S.M. Meeker, K.S. Mears, N. Sangwan, M.J. Brittnacher, E.J. Weiss, P.M. Treuting, N. Tolley, 501 C.E. Pope, K.R. Hager, A.T. Vo, J. Paik, C.W. Frevert, H.S. Hayden, L.R. Hoffman, S.I. Miller, 502 A.M. Hajjar, CFTR Dysregulation Drives Active Selection of the Gut Microbiome, PLoS Pathog. 503 16 (2020) e1008251. https://doi.org/10.1371/journal.ppat.1008251.
- M.B. De Freitas, E.A.M. Moreira, C. Tomio, Y.M.F. Moreno, F.P. Daltoe, E. Barbosa, N.L. 504 [12] 505 Neto, V. Buccigrossi, A. Guarino, Altered Intestinal Microbiota Composition, Antibiotic Therapy 506 and Intestinal Inflammation in Children and Adolescents with Cystic Fibrosis, PLoS One. 13 507 (2018) e0198457. https://doi.org/10.1371/journal.pone.0198457.
- T. Flass, S. Tong, D.N. Frank, B.D. Wagner, C.E. Robertson, C.V. Kotter, R.J. Sokol, E. 508 [13] 509 Zemanick, F. Accurso, E.J. Hoffenberg, M.R. Narkewicz, Intestinal Lesions are Associated 510 with Altered Intestinal Microbiome and are More Frequent in Children and Young Adults with 511 Cystic Fibrosis and Cirrhosis, PLoS One. 10 (2015) e0116967. 512 https://doi.org/10.1371/journal.pone.0116967.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24301982; this version posted February 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

- 513 [14] G. Dayama, S. Priya, D.E. Niccum, A. Khoruts, R. Blekhman, Interactions Between the Gut
  514 Microbiome and Host Gene Regulation in Cystic Fibrosis, Genome Med. 12 (2020) 12.
  515 https://doi.org/10.1186/s13073-020-0710-2.
- 516 [15] C.Y. Ooi, S.A. Syed, L. Rossi, M. Garg, B. Needham, J. Avolio, K. Young, M.G. Surette, T.
  517 Gonska, Impact of CFTR Modulation with Ivacaftor on Gut Microbiota and Intestinal
  518 Inflammation, Sci. Rep. 8 (2018). https://doi.org/10.1038/s41598-018-36364-6.
- [16] N.J. Ronan, G.G. Einarsson, J. Deane, F. Fouhy, M. Rea, C. Hill, F. Shanahan, J.S. Elborn,
  R.P. Ross, M. McCarthy, D.M. Murphy, J.A. Eustace, T. MM, C. Stanton, B.J. Plant,
  Modulation, Microbiota and Inflammation in the adult CF Gut: A Prospective Study, J. Cyst.
  Fibros. 21 (2022) 837–843. https://doi.org/10.1016/j.jcf.2022.06.002.
- 523 [17] C.E. Pope, A.T. Vo, H.S. Hayden, E.J. Weiss, S. Durfey, S. McNamara, A. Ratjen, B. Grogan,
  524 S. Carter, L. Nay, M.R. Parsek, P.K. Singh, E.F. McKone, M.L. Aitken, M.R. Rosenfeld, L.R.
  525 Hoffman, Changes in Fecal Microbiota with CFTR Modulator Therapy: A Pilot Study, J. Cyst.
  526 Fibros. 20 (2021) 742–746. https://doi.org/10.1016/j.jcf.2020.12.002.
- M.I. Kristensen, K.M. de Winter-De Groot, G. Berkers, M.L.J.N. Chu, K. Arp, S. Ghijsen,
  H.G.M. Heijerman, H.G.M. Arets, C.J. Majoor, H.M. Janssens, R. van der Meer, D. Bogaert,
  C.K. van der Ent, Individual and Group Response of Treatment with Ivacaftor on Airway and
  Gut Microbiota in People with CF and a s1251n Mutation, J. Pers. Med. 11 (2021) 350.
  https://doi.org/10.3390/jpm11050350.
- [19] R. Marsh, C. Dos Santos, L. Hanson, C. Ng, G. Major, A.R. Smyth, D. Rivett, C. van der Gast,
  Tezacaftor/Ivacaftor Therapy has Negligible Effects on the Cystic Fibrosis Gut Microbiome.,
  Microbiol. Spectr. 11 (2023) e0117523. https://doi.org/10.1128/spectrum.01175-23.
- 535 [20] C. Tetard, M. Mittaine, S. Bui, F. Beaufils, P. Maumus, M. Fayon, P.-R. Burgel, T. Lamireau, L.
   536 Delhaes, E. Mas, R. Enaud, Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in
   537 Adolescents With Cystic Fibrosis, J. Pediatr. Gastroenterol. Nutr. 71 (2020) 778–781.
- V.A. Stallings, N. Sainath, M. Oberle, C. Bertolaso, J.I. Schall, Energy Balance and
   Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations, J.
   Pediatr. 201 (2018) 229-237.e4. https://doi.org/10.1016/j.jpeds.2018.05.018.
- 541 [22] S.N. Dawood, A.M. Rabih, A. Niaj, A. Raman, M. Uprety, M.J. Calero, M.R.B. Villanueva, N.
  542 Joshaghani, N. Villa, O. Badla, R. Goit, S.E. Saddik, L. Mohammed, Newly Discovered
  543 Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review., Cureus. 14
  544 (2022) e29359. https://doi.org/10.7759/cureus.29359.
- 545 [23] C. Ng, N.S. Dellschaft, C.L. Hoad, L. Marciani, L. Ban, A.P. Prayle, H.L. Barr, A. Jaudszus,
  546 J.G. Mainz, R.C. Spiller, P. Gowland, G. Major, A.R. Smyth, Postprandial Changes in
  547 Gastrointestinal Function and Transit in Cystic Fibrosis Assessed by Magnetic Resonance
  548 Imaging, J. Cyst. Fibros. 20 (2021) 591–597. https://doi.org/10.1016/j.jcf.2020.06.004.
- [24] R. Marsh, H. Gavillet, L. Hanson, C. Ng, M. Mitchell-Whyte, G. Major, A.R. Smyth, D. Rivett, C. van der Gast, Intestinal Function and Transit Associate with Gut Microbiota Dysbiosis in Cystic
  Fibrosis., J. Cyst. Fibros. 21 (2022) 506–513.
  https://doi.org/10.1016/j.jcf.2021.11.014.
- L. Frank, L. Kleinman, C. Farup, L. Taylor, P.J. Miner, Psychometric Validation of a
  Constipation Symptom Assessment Questionnaire., Scand. J. Gastroenterol. 34 (1999) 870–
  877. https://doi.org/10.1080/003655299750025327.
- [26] M.A. Gorzelak, S.K. Gill, N. Tasnim, Z. Ahmadi-Vand, M. Jay, D.L. Gibson, Methods for
  Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing
  and Storage of Stool, PLoS One. 10 (2015) e0134802.
  https://doi.org/10.1371/journal.pone.0134802.
- 560 [27] G.B. Rogers, L. Cuthbertson, L.R. Hoffman, P.A.C. Wing, C. Pope, D.A.P. Hooftman, A.K.
  561 Lilley, A. Oliver, M.P. Carroll, K.D. Bruce, C.J. Van Der Gast, Reducing Bias in Bacterial
  562 Community Analysis of Lower Respiratory Infections, ISME J. 7 (2013) 697–706.
  563 https://doi.org/10.1038/ismej.2012.145.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24301982; this version posted February 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 564 [28] B.J. Callahan, P.J. McMurdie, M.J. Rosen, A.W. Han, A.J.A. Johnson, S.P. Holmes, DADA2: 565 High Resolution Sample Inference from Illumina Amplicon Data, Nat. Methods. 13 (2016) 4–5. 566 https://doi.org/10.1038/nmeth.3869.DADA2.
- N.M. Davis, D.M. Proctor, S.P. Holmes, D.A. Relman, B.J. Callahan, Simple Statistical 567 [29] 568 Identification and Removal of Contaminant Sequences in Marker-Gene and Metagenomics 569 Data, Microbiome. 6 (2018) 226. https://doi.org/10.1186/s40168-018-0605-2.
- [30] 570 Ø. Hammer, D. A.T. Harper, P.D. Rvan, PAST: Paleontological Statistics Software Package for Education and Data Analysis, Palaeontol. Electron. 4 (2001) 9. 571
- [31] 572 C. ter Braak, P. Smilauer, CANOCO Reference Manual and User's Guide: Software for Ordination., Ithaca: Microcomputer Power, 2012. 573
- 574 [32] F. Miragoli, S. Federici, S. Ferrari, A. Minuti, A. Rebecchi, E. Bruzzese, V. Buccigrossi, A. 575 Guarino, M.L. Callegari, Impact of Cystic Fibrosis Disease on Archaea and Bacteria 576 Composition of Gut Microbiota, FEMS Microbiol. Ecol. 93 (2017) fiw230. 577 https://doi.org/10.1093/femsec/fiw230.
- 578 O. Manor, R. Levy, C.E. Pope, H.S. Hayden, M.J. Brittnacher, R. Carr, M.C. Radey, K.R. [33] 579 Hager, S.L. Heltshe, B.W. Ramsey, S.I. Miller, L.R. Hoffman, E. Borenstein, Metagenomic 580 Evidence for Taxonomic Dysbiosis and Functional Imbalance in the Gastrointestinal Tracts of Children with Cystic Fibrosis, Sci. Rep. 6 (2016) 22493. https://doi.org/10.1038/srep22493. 581
- M. Sakamoto, N. Sakurai, H. Tanno, T. Iino, M. Ohkuma, A. Endo, Genome-Based, 582 [34] 583 Phenotypic and Chemotaxonomic Classification of Faecalibacterium Strains: Proposal of 584 Three Novel Species Faecalibacterium duncaniae sp. nov., Faecalibacterium hattorii sp. nov. 585 and Faecalibacterium gallinarum sp. nov., Int. J. Syst. Evol. Microbiol. 72 (2022) 005379. 586 https://doi.org/10.1099/ijsem.0.005379.
- 587 [35] D. Parada Venegas, M.K. De la Fuente, G. Landskron, M.J. González, R. Quera, G. Dijkstra, 588 H.J.M. Harmsen, K.N. Faber, M.A. Hermoso, Short Chain Fatty Acids (SCFAs)-Mediated Gut 589 Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases, Front. 590 Immunol. 10 (2019) 277. https://www.frontiersin.org/articles/10.3389/fimmu.2019.00277.
- 591 [36] B.L. Baldwin-Hunter, F.D. Rozenberg, M.K. Annavajhala, H. Park, E.A. DiMango, C.L. Keating, 592 A.-C. Uhlemann, J.A. Abrams, The Gut Microbiome, Short Chain Fatty Acids, and Related 593 Metabolites in Cystic Fibrosis Patients with and without Colonic Adenomas., J. Cyst. Fibros. 22 594 (2023) 738-744. https://doi.org/10.1016/j.jcf.2023.01.013.
- 595 [37] Y. Wang, L.E.X. Leong, R.L. Keating, T. Kanno, G.C.J. Abell, F.M. Mobegi, J.M. Choo, S.L. 596 Wesselingh, A.J. Mason, L.D. Burr, G.B. Rogers, Opportunistic Bacteria Confer the Ability 597 toFerment Prebiotic Starch in the Adult Cystic Fibrosis Gut, Gut Microbes. 10 (2019) 367–381. https://doi.org/10.1080/19490976.2018.1534512. 598
- 599 [38] P. Vernocchi, F. Del Chierico, A. Russo, F. Majo, M. Rossitto, M. Valerio, L. Casadei, A. La 600 Storia, F. De Filippis, C. Rizzo, C. Manetti, P. Paci, D. Ercolini, F. Marini, E.V. Fiscarelli, B. 601 Dallapiccola, V. Lucidi, A. Miccheli, L. Putignani, Gut microbiota signatures in cystic fibrosis: 602 Loss of host CFTR function drives the microbiota enterophenotype, PLoS One. 13 (2018) 603 e0208171. https://doi.org/10.1371/journal.pone.0208171.
- 604 [39] V. De Preter, K. Machiels, M. Joossens, I. Arijs, C. Matthys, S. Vermeire, P. Rutgeerts, K. 605 Verbeke, Faecal Metabolite Profiling Identifies Medium-Chain Fatty Acids as Discriminating Compounds in IBD., Gut. 64 (2015) 447-458. https://doi.org/10.1136/gutjnl-2013-306423. 606
- 607 G. Duytschaever, G. Huys, M. Bekaert, L. Boulanger, K. De Boeck, P. Vandamme, Dysbiosis [40] 608 of Bifidobacteria and Clostridium Cluster XIVa in the Cystic Fibrosis Fecal Microbiota, J. Cyst. 609 Fibros. 12 (2013) 206–215. https://doi.org/10.1016/j.jcf.2012.10.003.
- 610 R. Enaud, K.B. Hooks, A. Barre, T. Barnetche, C. Hubert, M. Massot, T. Bazin, H. Clouzeau, [41] S. Bui, M. Fayon, P. Berger, P. Lehours, C. Bébéar, M. Nikolski, T. Lamireau, L. Delhaes, T. 611 612 Schaeverbeke, Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with 613 Crohn's-Like Microbiota Disturbances, J. Clin. Med. 8 (2019) 645. https://doi.org/10.3390/jcm8050645. 614

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24301982; this version posted February 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

- [42] R.H. Keogh, R. Cosgriff, E.R. Andrinopoulou, K.G. Brownlee, S.B. Carr, K. Diaz-Ordaz, E.
  Granger, N.P. Jewell, A. Lewin, C. Leyrat, D.K. Schlüter, M. van Smeden, R.D. Szczesniak,
  G.J. Connett, Projecting the Impact of Triple CFTR Modulator Therapy on Intravenous
  Antibiotic Requirements in Cystic Fibrosis using Patient Registry Data Combined with
  Treatment Effects from Randomised Trials, Thorax. 77 (2022) 873–881.
  https://doi.org/10.1136/thoraxjnl-2020-216265.
- [43] N. Dellschaft, C. Hoad, L. Marciani, P. Gowland, R. Spiller, Small Bowel Water Content
  Assessed by MRI in Health and Disease: A Collation of Single-Centre Studies., Aliment.
  Pharmacol. Ther. 55 (2022) 327–338. https://doi.org/10.1111/apt.16673.
- [44] A. Rivière, M. Selak, D. Lantin, F. Leroy, L. De Vuyst, Bifidobacteria and Butyrate-Producing
   Colon Bacteria: Importance and Strategies for their Stimulation in the Human Gut, Front.
   Microbiol. 7 (2016) 979. https://doi.org/10.3389/fmicb.2016.00979.
- M.T. Henke, D.J. Kenny, C.D. Cassilly, H. Vlamakis, R.J. Xavier, J. Clardy, Ruminococcus
  gnavus, a Member of the Human Gut Microbiome Associated with Crohn's Disease, Produces
  an Inflammatory Polysaccharide, Proc. Natl. Acad. Sci. U. S. A. 116 (2019) 12672–12677.
  https://doi.org/10.1073/pnas.1904099116.
- [46] F. Fouhy, N.J. Ronan, O. O'Sullivan, Y. McCarthy, A.M. Walsh, D.M. Murphy, M. Daly, E.T.
  Flanagan, C. Fleming, M. McCarthy, C. Shortt, J.A. Eustace, F. Shanahan, M.C. Rea, R.P.
  Ross, C. Stanton, B.J. Plant, A Pilot Study Demonstrating the Altered Gut Microbiota
  Functionality in Stable Adults with Cystic Fibrosis, Sci. Rep. 7 (2017) 6685.
  https://doi.org/10.1038/s41598-017-06880-y.
- [47] S.L. Taylor, L.E.X. Leong, S.K. Sims, R.L. Keating, L.E. Papanicolas, A. Richard, F.M. Mobegi,
  S. Wesselingh, L.D. Burr, G.B. Rogers, The Cystic Fibrosis Gut as a Potential Source of
  Multidrug Resistant Pathogens., J. Cyst. Fibros. 20 (2021) 413–420.
  https://doi.org/10.1016/j.jcf.2020.11.009.
- [48] I. Testa, O. Crescenzi, S. Esposito, Gut Dysbiosis in Children with Cystic Fibrosis:
  Development, Features and the Role of Gut-Lung Axis on Disease Progression.,
  Microorganisms. 11 (2022) 9. https://doi.org/10.3390/microorganisms11010009.
- A.G. Hoen, J. Lia, L.A. Moulton, G.A. O'Toole, M.L. Housman, D.C. Koestler, M.F. Guill, J.H.
  Moore, P.L. Hibberd, H.G. Morrison, M.L. Sogin, M.R. Karagas, J.C. Madan, Associations
  Between Gut Microbial Colonization in Early Life and Respiratory Outcomes in Cystic Fibrosis,
  J. Pediatr. 167 (2015) 138-147.e1–3. https://doi.org/110.1016/j.bbi.2017.04.008.
- L.R. Hoffman, C.E. Pope, H.S. Hayden, S. Heltshe, R. Levy, S. McNamara, M.A. Jacobs, L.
  Rohmer, M. Radey, B.W. Ramsey, M.J. Brittnacher, E. Borenstein, S.I. Miller, Escherichia coli
  Dysbiosis Correlates with Gastrointestinal Dysfunction in Children with Cystic Fibrosis, Clin.
  Infect. Dis. 58 (2014) 396–399. https://doi.org/10.1093/cid/cit715.
- [51] S. Matamouros, H.S. Hayden, K.R. Hager, M.J. Brittnacher, K. Lachance, E.J. Weiss, C.E.
  Pope, A.F. Imhaus, C.P. McNally, E. Borenstein, L.R. Hoffman, S.I. Miller, Adaptation of
  Commensal Proliferating Escherichia coli to the Intestinal Tract of Young Children with Cystic
  Fibrosis, Proc. Natl. Acad. Sci. U. S. A. 115 (2018) 1605–1610.
  https://doi.org/10.1073/pnas.1714373115.
- 656 [52] S. Arboleya, C. Watkins, C. Stanton, R.P. Ross, Gut Bifidobacteria Populations in Human
  657 Health and Aging., Front. Microbiol. 7 (2016) 1204. https://doi.org/10.3389/fmicb.2016.01204.
- J.G. Mainz, C. Zagoya, L. Polte, L. Naehrlich, L. Sasse, O. Eickmeier, C. Smaczny, A.
  Barucha, L. Bechinger, F. Duckstein, L. Kurzidim, P. Eschenhagen, L. Caley, D. Peckham, C.
  Schwarz, Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic
  Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score, Front. Pharmacol. 14
  (2022) 1207356. https://doi.org/10.3389/fphar.2022.877118.
- 663 [54] A. Munck, Cystic Fibrosis: Evidence for Gut Inflammation., Int. J. Biochem. Cell Biol. 52 (2014)
  180–183. https://doi.org/10.1016/j.biocel.2014.02.005.
- 665 [55] F. Beaufils, E. Mas, M. Mittaine, M. Addra, M. Fayon, L. Delhaes, H. Clouzeau, F. Galode, T.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.01.24301982; this version posted February 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

- Lamireau, Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms
   and Quality of Life Scores in Children with Cystic Fibrosis, J. Clin. Med. 9 (2020) 4080.
- J. Dorsey, T. Gonska, Bacterial Overgrowth, Dysbiosis, Inflammation, and Dysmotility in the
  Cystic Fibrosis Intestine, J. Cyst. Fibros. 16 (2017) S14–S23.
  https://doi.org/10.1016/j.jcf.2017.07.014.
- [57] V.A. Stallings, N. Sainath, M. Oberle, C. Bertolaso, J.I. Schall, Energy Balance and
  Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations, J.
  Pediatr. 201 (2018) 229-237.e4. https://doi.org/https://doi.org/10.1016/j.jpeds.2018.05.018.
- 674 [58] C. Tétard, M. Mittaine, S. Bui, M. Beaufils, F., Maumus, P. Fayon, P.R. Burgel, T. Lamireau, L.
  675 Delhaes, E. Mas, R. Enaud, Reduced Intestinal Inflammation with Lumacaftor/Ivacaftor in
  676 Adolescents with Cystic Fibrosis, J. Pediatr. Gastroenterol. Nutr. 71 (2020) 778–781.
- [59] S.J. Schwarzenberg, P.T. Vu, M. Skalland, L.R. Hoffman, C. Pope, D. Gelfond, M.R.
  Narkewicz, D.P. Nichols, S.L. Heltshe, S.H. Donaldson, C.A. Frederick, A. Kelly, J.E. Pittman,
  F. Ratjen, M. Rosenfeld, S.D. Sagel, G.M. Solomon, M.S. Stalvey, J.P. Clancy, S.M. Rowe,
  S.D. Freedman, Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic
  Fibrosis: Report of Promise-GI., J. Cyst. Fibros. 22 (2022) 282–289.
  https://doi.org/10.1016/j.jcf.2022.10.003.
- [60] C.J. van der Gast, A.W. Walker, F.A. Stressmann, G.B. Rogers, P. Scott, T.W. Daniels, M.P.
  Carroll, J. Parkhill, K.D. Bruce, Partitioning core and satellite taxa from within cystic fibrosis
  lung bacterial communities., ISME J. 5 (2011) 780–791.
  https://doi.org/10.1038/ismej.2010.175.
- 687 [61] A.E. Magurran, Species Abundance Distributions Over Time, Ecol. Lett. 10 (2007) 347–354.
   688 https://doi.org/https://doi.org/10.1111/j.1461-0248.2007.01024.x.
- [62] L.R. Caley, H. White, M.C. de Goffau, R.A. Floto, J. Parkhill, B. Marsland, D.G. Peckham,
  Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review., Dig. Dis. Sci. 68 (2023) 1797–
  1814. https://doi.org/10.1007/s10620-022-07812-1.
- [63] S. Esposito, I. Testa, E. Mariotti Zani, D. Cunico, L. Torelli, R. Grandinetti, V. Fainardi, G. Pisi,
   N. Principi, Probiotics Administration in Cystic Fibrosis: What Is the Evidence?, Nutrients. 14
   (2022) 3160. https://doi.org/10.3390/nu14153160.
- [64] I. McKay, J. van Dorst, T. Katz, M. Doumit, B. Prentice, L. Owens, Y. Belessis, S. Chuang, A. Jaffe, T. Thomas, M. Coffey, C.Y. Ooi, Diet and the gut-lung axis in cystic fibrosis direct & indirect links., Gut Microbes. 15 (2023) 2156254.
  698 https://doi.org/10.1080/19490976.2022.2156254.
- [65] R.L. Knoll, V.H. Jarquín-Díaz, J. Klopp, A. Kemper, K. Hilbert, B. Hillen, D. Pfirrmann, P.
  700
  701
  701
  702
  703
  704
  705
  705
  706
  706
  707
  707
  708
  708
  709
  709
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  701
  701
  701
  702
  702
  703
  704
  704
  705
  705
  706
  707
  707
  708
  708
  709
  709
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700
  700</li
- J.L. Taylor-Cousar, P.D. Robinson, M. Shteinberg, D.G. Downey, CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis., Lancet. 402 (2023) 1171–1184. https://doi.org/10.1016/S0140-6736(23)01609-4.
- K.B. Hisert, S.E. Birket, J.P. Clancy, D.G. Downey, J.F. Engelhardt, I. Fajac, R.D. Gray, M.E.
  Lachowicz-Scroggins, N. Mayer-Hamblett, P. Thibodeau, K.L. Tuggle, C.E. Wainwright, K. De
  Boeck, Understanding and addressing the needs of people with cystic fibrosis in the era of
  CFTR modulator therapy, Lancet Respir. Med. 11 (2023) 916–931.
  https://doi.org/https://doi.org/10.1016/S2213-2600(23)00324-7.
- [68] G.A. O'Toole, A. Crabbé, R. Kümmerli, J.J. LiPuma, J.M. Bomberger, J.C. Davies, D. Limoli,
  V. V Phelan, J.B. Bliska, W.H. DePas, L.E. Dietrich, T.H. Hampton, R. Hunter, C.M.
  Khursigara, A. Price-Whelan, A. Ashare, R.A. Cramer, J.B. Goldberg, F. Harrison, D.A. Hogan,
  M.A. Henson, D.R. Madden, J.R. Mayers, C. Nadell, D. Newman, A. Prince, D.W. Rivett, J.D.
  Schwartzman, D. Schultz, D.C. Sheppard, A.R. Smyth, M.A. Spero, B.A. Stanton, P.E. Turner,
  C. van der Gast, F.J. Whelan, R. Whitaker, K. Whiteson, Model Systems to Study the Chronic,

- Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions, MBio. 12 (2021) e0176321. https://doi.org/10.1128/mbio.01763-21. 717
- 718